Virax Biolabs Group Ltd
VRAX · In Vitro & In Vivo Diagnostic Substances · EDGAR filings ↗
Grade
D44Clinical-stage diagnostics company with negligible revenue, deep losses and a pre-commercial pipeline.
Strengths
- Strong current/quick ratio (~7x, 84th pct) and cash runway ~3.3 quarters
- FDA Q-submission underway for the ViraxImmune T-cell platform
Risks
- Negative gross margin and net loss ~$6.1m; accumulated deficit $24.6m and no product revenue
- Binary regulatory/commercialization risk with recurring dilution to fund operations
Notable findings
- RestatementThe Company filed the third amended and restated articles of association (the “Post-Split Amended and Restated Articles of Association”), which became effective on December 18, 2023 8-K ↗
- Net lossNet loss (net margin -95833.7%)
- Cash burnNegative free cash flow (-5.2M)
Key metrics
Gross margin
-838.2%
Operating margin
-97344.8%
Net margin
-95833.7%
Return on equity
-111.1%
Return on assets
-94.4%
Current ratio
7.3×
Free cash flow
-$5M
Tangible book value
$5M
Cash & investments
$4M
Cash runway
3q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-07-02 | 2025-03-31 | 0000950170-25-093260 ↗ |
| 20-F | 2024-08-20 | 2024-03-31 | 0000950170-24-099115 ↗ |
| 20-F | 2023-06-14 | 2023-03-31 | 0000950170-23-027973 ↗ |
| 20-F | 2022-08-12 | 2022-03-31 | 0000950170-22-017130 ↗ |